Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).
Dong-Wan Kim
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Myung-Ju Ahn
No relevant relationships to disclose
Yuankai Shi
No relevant relationships to disclose
Tommaso Martino De Pas
No relevant relationships to disclose
Pan-Chyr Yang
No relevant relationships to disclose
Gregory J. Riely
Consultant or Advisory Role - Abbott Molecular; ARIAD; Chugai Pharma; Daiichi Sankyo; Tragara Pharmaceuticals (U)
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Infinity; Merck Serono; Pfizer
Lucio Crinò
Honoraria - ECCO-ESMO
Tracey L. Evans
No relevant relationships to disclose
Xiaoqing Liu
No relevant relationships to disclose
Ji-Youn Han
No relevant relationships to disclose
Ravi Salgia
No relevant relationships to disclose
Denis Moro-Sibilot
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Other Remuneration - Pfizer
Sai-Hong Ignatius Ou
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
Scott N. Gettinger
Research Funding - Pfizer
Yi Long Wu
Honoraria - AstraZeneca; Lilly; Pfizer; Roche
Silvana Lanzalone
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Anna Polli
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Shrividya Iyer
Employment or Leadership Position - Pfizer
Alice Tsang Shaw
Consultant or Advisory Role - ARIAD; Chugai Pharma; Daiichi Sankyo; Pfizer
Honoraria - Millennium; Novartis
Research Funding - ARIAD; AstraZeneca; Novartis; Pfizer